Quality by design (QbD) approaches in current pharmaceutical set-up
INTRODUCTION: Quality by design (QbD) encourages the pharmaceutical industry to use risk management and science-based manufacturing principles to gain process and product understanding and thus assures quality of the product. With the objective to curb the rising costs for development and regulatory barriers to innovation and creativity, QbD is being widely promoted by Food and Drug Administration (FDA) and International Conference on Harmonization (ICH).
AREAS COVERED: This review describes the elements, different design and tools of QbD as well as multidimensional applications of QbD ranging from dosage form and method development to meeting latest regulatory requirements.
EXPERT OPINION: The understanding of a process is facilitated by proper identification of sources of variation, management of variability by process design, and prediction of product quality attributes using design space. The pharmaceutical industry is rapidly adopting the QbD principles for fabrication of safe, effective and quality products; however, we are still on a journey and the process of gathering all experience and metrics required for connecting and demonstrating QbD benefits to all stakeholders is still in progress. Understanding the formulation and process parameters with the philosophy of QbD will be useful for the optimization of complex drug delivery systems in the near future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 15(2018), 8 vom: 15. Aug., Seite 737-758 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mishra, Vijay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug delivery system |
|---|
| Anmerkungen: |
Date Completed 01.02.2019 Date Revised 23.07.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425247.2018.1504768 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286848430 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286848430 | ||
| 003 | DE-627 | ||
| 005 | 20231225052658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2018.1504768 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0956.xml |
| 035 | |a (DE-627)NLM286848430 | ||
| 035 | |a (NLM)30044646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mishra, Vijay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality by design (QbD) approaches in current pharmaceutical set-up |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2019 | ||
| 500 | |a Date Revised 23.07.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Quality by design (QbD) encourages the pharmaceutical industry to use risk management and science-based manufacturing principles to gain process and product understanding and thus assures quality of the product. With the objective to curb the rising costs for development and regulatory barriers to innovation and creativity, QbD is being widely promoted by Food and Drug Administration (FDA) and International Conference on Harmonization (ICH) | ||
| 520 | |a AREAS COVERED: This review describes the elements, different design and tools of QbD as well as multidimensional applications of QbD ranging from dosage form and method development to meeting latest regulatory requirements | ||
| 520 | |a EXPERT OPINION: The understanding of a process is facilitated by proper identification of sources of variation, management of variability by process design, and prediction of product quality attributes using design space. The pharmaceutical industry is rapidly adopting the QbD principles for fabrication of safe, effective and quality products; however, we are still on a journey and the process of gathering all experience and metrics required for connecting and demonstrating QbD benefits to all stakeholders is still in progress. Understanding the formulation and process parameters with the philosophy of QbD will be useful for the optimization of complex drug delivery systems in the near future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Quality by design | |
| 650 | 4 | |a drug delivery system | |
| 650 | 4 | |a nanocarrier | |
| 650 | 4 | |a process design | |
| 650 | 4 | |a product design | |
| 650 | 4 | |a risk management | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Thakur, Sourav |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Akshay |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Anshuman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 15(2018), 8 vom: 15. Aug., Seite 737-758 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2018 |g number:8 |g day:15 |g month:08 |g pages:737-758 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2018.1504768 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2018 |e 8 |b 15 |c 08 |h 737-758 | ||